Table 1.

Demographic and clinical data

	Control group n=30	Group A n=30	Group B n=30	Group C n=30
Age (Years)	48.96 ± 11.16	49.60 ± 13.02	50.13 ± 11.74	49.73 ± 9.51
Sex	Male:13	Male:14	Male:15	Male:15
	Female:17	Female:16	Female:15	Female:15
BMI (kg/m2)	26.77 ± 2.53	32.01 ± 4.97	31.67 ± 4.29	33.38 ± 5.83
WC(cm)	84.60±6.34	103.73±7.68	102.96±9.47	111.03±12.02
SBP (mm/Hg)	120.50 ± 8.94	128.40 ± 18.43	129.27 ± 8.88	128.17 ± 13.74
DBP(mm/Hg)	77.00 ± 6.51	81.23 ± 9.87	77.00 ± 6.27	79.00 ± 5.93
Triglyceride (mg/dL)	112.57 ± 50.76	158.5 ± 65.90	143.43 ± 74.38	160.73 ± 58.40
Total cholesterol (mg/dL)	166 ± 23.72	182 ± 45.53	225 ± 64.56	195 ± 54.92
Subjects with Neuropathy (n;%)	None	3; 10	5; 16.67	7; 23.33
Mean Diabetes Duration (months)	N/A	N/A	19.23±14.96	22.26±17.53

BMI: Body Mass Index, WC: Waist Circumference, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, N/A: not applicable Control group: Healthy subjects (n=30)

Group A: Subjects with metabolic syndrome HbA1c levels <% 5.7 (n=30)

Group B: Subjects with metabolic syndrome HbA1c levels between ≥% 5.7, <% 6.5 (n=30)

Group C: Subjects with metabolic syndrome HbA1c levels between ≥% 6.5, <% 8.0 (n=30).